BioTime, Inc. and its recently formed subsidiary BioTime Acquisition Corporation jointly announced today that they have entered into a definitive Asset Contribution Agreement with Geron Corporation to acquire the intellectual property, including patents and patent applications, and other assets related to Geron's human embryonic stem cell programs ... (more)
http://www.benzinga.com/news/13/01/3218715/biotime-to-buy-human-embryonic-stem-cell-program-assets-of-geron
http://www.benzinga.com/news/13/01/3218715/biotime-to-buy-human-embryonic-stem-cell-program-assets-of-geron
No comments:
Post a Comment